All In Biotech

Free tool

FAERS Monitor: Edurant Ped

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219016 or its brand name (Edurant Ped, Rilpivirine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

55

Serious

52

95% of reports

Hospitalization

15

Death reported

6

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • depressed mood4
  • drug interaction4
  • insomnia4
  • off label use4
  • rash4
  • abnormal dreams3
  • acute kidney injury3
  • confusional state3
  • depression3
  • disorientation3
  • fatigue3
  • haemoglobin decreased3
  • hallucination3
  • hepatotoxicity3
  • hyperuricaemia3

Reports by year received

View as table
YearReports
20111
20121
20133
20144
20155
20166
20174
20188
20199
20203
20211
20223
20233
20242
20251
20261

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,104 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hyperuricaemiaSignal3279.392.9577
hepatotoxicitySignal351.517.1103
abnormal dreamsSignal341.613.882
disorientationSignal329.09.656
depressed moodSignal428.911.382
hallucinationSignal315.25.127
haemoglobin decreasedSignal311.23.719
drug interactionSignal49.63.823
acute kidney injurySignal37.52.511
confusional stateSignal37.12.410
insomniaSignal45.72.211
depressionSignal35.01.76
rashSignal43.51.45
off label use41.70.71
fatigue31.50.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.